Tag Archives: candesartan
February 2011 Br J Cardiol 2011;18:9-10
Heart failure registry looks at mortality with ARBs
BJ Cardio Staff
The registry study, published in Journal of the American Medical Association (January 12th, 2011 issue), involved 30,254 patients, of whom 2,500 were taking losartan and 2,639 were taking candesartan. One-year survival was 90% for patients receiving candesartan and 83% for those taking losartan. Five-year survival was 61% and 44%, respectively. In multivariate analysis with adjustment for propensity scores, the hazard ratio for mortality for losartan compared with candesartan was 1.43 (p<0.001). The authors, led by Dr Maria Eklind-Cervenka (South Hospital, Stockholm, Sweden) note that the difference remained significant even after adjustme
March 2008 Br J Cardiol 2008;15:71
In brief
BJCardio editorial team
New editorial board member We welcome general practitioner and diabetologist, Dr Neil Munro (left) to the BJC editorial board.Dr Munro has been a general practitioner in Surrey since 1984. He is also an Associate Specialist in Diabetes at the Chelsea and Westminster Hospital, London, and has worked in specialist hospital-based diabetes clinics since 1985. In addition, he has provided diabetes services for the practice for over two decades. He was research officer for the St Vincent’s Declaration Primary Care Diabetes Group in 1999 and Chairman of Primary Care Diabetes Europe (PCDE) from 2000–2005. His appointment underlines the BJC’s
January 2005 Br J Cardiol 2005;12:31-6
The role of candesartan in the treatment of chronic heart failure
Hugh F McIntyre
No content available
May 2002 Br J Cardiol 2002;9:280-6
Angiotensin II receptor antagonists in the treatment of heart failure: background to and design of the CHARM study
Simon W Dubrey
No content available
For healthcare professionals only
